Citranvi is a pre-clinical stage company that provides end-to-end solutions for the design and development of novel systems and tools for immunogenicity enhancement, applicable to Vaccines Research and Development. Our special focus is on Conjugate Vaccine Development and Nanoparticle Technologies, applicable for Multi-component Prophylactic and Immunotherapeutic Nanovaccines. ​

We are developing innovative, proprietary vaccine technologies and products, using comprehensive Structure-based Vaccine Design, broadly applicable to a variety of preventable disease targets, where there is an unmet medical need, across the globe.